Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
Anti-PD-L1 therapy often fails in cancers with minimal lymphocytic infiltrates and low PD-L1 expression. Here, the authors show that an oncolytic virus increases PD-L1 expression in cancer models and that the combination with an anti-PD-L1 antibody enhances therapy by increasing the infiltration of...
Guardado en:
Autores principales: | Zuqiang Liu, Roshni Ravindranathan, Pawel Kalinski, Z. Sheng Guo, David L. Bartlett |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/08d52995317b46989e958cc19d18bdfc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Yi Wang, et al.
Publicado: (2021) -
Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
por: Chun-Yu Chen, et al.
Publicado: (2017) -
Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021) -
Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
por: Zuqiang Liu, et al.
Publicado: (2018) -
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Xiaoyan Zhang, et al.
Publicado: (2021)